AimedBio Signs Strategic Collaboration with Inocras to Advance Precision Medicine-driven Oncology Drug Development
2026.06.26
- AimedBio has entered a strategic collaboration and equity investment agreement with Inocras to advance precision medicine–based drug development.
- The partnership will leverage Inocras’s whole genome sequencing (WGS) and multi-omics capabilities to support AimedBio’s ADC clinical development.
- Key areas of collaboration include biomarker analysis, patient stratification, and identification of new oncology targets.
Inocras operates a CLIA/CAP-certified genomic testing platform and provides cancer genomics services such as CancerVision and MRDVision.
- AimedBio plans to apply WGS-based biomarker insights across current and future ADC clinical trials to improve patient selection and expand indications.
- The companies will also explore joint commercialization opportunities combining precision diagnostics and drug development platforms.
